Background: An Alzheimer’s disease (AD) is generally concerned with outer settling of amyloid-β which is in the state of neuritis and diffused plaques and it also shows the existence of neuropil threads and intraneuronal neurofibrillary tangles inside dystrophic neuritis which consisted of aggregated hyper phosphorylated tau protein. Main body of the abstract: Dementia is a disorder associated with AD is in relation with the onset of extensive and revolutionary incapacity for the duration of the sickness direction with demise an inevitable outcome, typically going on for period of [5-12 years] of symptom onset. There’s a dire want for ailment editing remedies which may also stop or sluggish fee of ailment progression, however unluckily none are presently available. The statistical data of medical and pharmaceutical improvement for AD has been afflicted to medical trial failures. Nevertheless, enormous steps have been taken in recent decades in deeply studying the key factors for causing pathobiology of Alzheimer’s disease. However, the therapeutic pipeline of Alzheimer’s disease has confronted many difficulties and few pharma-tech groups have neglected the drug improvement in Alzheimer’s disease. Short conclusion: Novel drug delivery therapeutic methods for AD has been ignored and nevertheless being positively formulated and evaluated. This review article specifies about current research advances in the pathobiology of Alzheimer’s disease and also summarizes the various treatment strategies and opportunities and challenges faced while being on the road in development of a new therapeutic treatment.